Compounds > pyrazole-5-carboxamide
Page last updated: 2024-11-12

pyrazole-5-carboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pyrazole-5-carboxamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15239624
SCHEMBL ID1274
SCHEMBL ID9015448
MeSH IDM000601243

Synonyms (29)

Synonym
AC-6389
1h-pyrazole-5-carboxamide
c4h5n3o
33064-36-7
1h-pyrazole-3-carboxamide
AKOS005145965
FT-0650440
1h-pyrazole-3-carboxylic acid amide
A5905
pyrazole-3-carboxamide
AM20090500
CL3448
BNYCHCAYYYRJSH-UHFFFAOYSA-N
pyrazole carboxamide
SCHEMBL1274
SCHEMBL9015448
DTXSID10570380
F8881-7759
mfcd11036164
J-524078
CS-W006006
SY033000
Z1095213382
pyrazole-5-carboxamide
AS-18302
BCP27108
2,2-(hydroxyimino)bis-(ethanesulfonicacid),disodiumsalt
EN300-84098
AT10771
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (66.67)24.3611
2020's5 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.85 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		2.610amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
pyrazole
1H-pyrazole : The 1H-tautomer of pyrazole.		7.1310pyrazole
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		2.1710monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
a 17
A 17: RN given refers to dibromide		2.1510
chalcone
trans-chalcone : The trans-isomer of chalcone.		7.1310chalconeEC 3.2.1.1 (alpha-amylase) inhibitor
vx-770
ivacaftor: a CFTR potentiator; structure in first source. ivacaftor : An aromatic amide obtained by formal condensation of the carboxy group of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid with the amino group of 5-amino-2,4-di-tert-butylphenol. Used for the treatment of cystic fibrosis.		2.1710aromatic amide;
monocarboxylic acid amide;
phenols;
quinolone		CFTR potentiator;
orphan drug
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Prostate
[description not available]		02.3110
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.3110
Electron Transport Chain Deficiencies, Mitochondrial
[description not available]		02.1510
Haemonchiasis
Infection with nematodes of the genus HAEMONCHUS, characterized by digestive abnormalities and anemia similar to that from hookworm infestation.		02.1510
Mitochondrial Diseases
Diseases caused by abnormal function of the MITOCHONDRIA. They may be caused by mutations, acquired or inherited, in mitochondrial DNA or in nuclear genes that code for mitochondrial components. They may also be the result of acquired mitochondria dysfunction due to adverse effects of drugs, infections, or other environmental causes.		02.1510
Cystic Fibrosis of Pancreas
[description not available]		02.1710
Cystic Fibrosis
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.		07.1710
Bacterial Disease
[description not available]		02.1310
Bacterial Infections
Infections by bacteria, general or unspecified.		02.1310